Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH – Get Free Report)’s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.00. Anthera Pharmaceuticals shares last traded at $0.00, with a volume of 659 shares changing hands.
Anthera Pharmaceuticals Trading Up 9,900.0 %
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.
Further Reading
- Five stocks we like better than Anthera Pharmaceuticals
- What is MarketRank™? How to Use it
- How to Invest in Micro-Cap Stocks Like a Pro
- How to Calculate Inflation Rate
- Investors Sell Microsoft Stock on OpenAI News—Time to Buy?
- Retail Stocks Investing, Explained
- Take-Two Interactive: A Defensive Play Set to Explode
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
